Gyre Therapeutics: employment agreements for CEO and CFO

What happened Gyre Therapeutics reported that on Oct 16, 2026 it entered into employment agreements with Ying Luo, Ph.D., to continue to serve as chief executive officer, and with Thomas Eastling to continue to serve as chief financial officer. The agreements provide at-will employment, participation in company benefit plans and specified compensation and severance terms.

Key details

• Ying Luo: annual base salary $500,000 and a 2026 target bonus of $150,000.
• Thomas Eastling: annual base salary $339,066 and a 2026 target bonus of $70,000.
• If terminated by Gyre without “Cause” or by the executive for “Good Reason”: salary continuation equal to then-current base salary paid over six months, COBRA premium reimbursement for up to 12 months if timely elected, and accelerated vesting of equity awards scheduled to vest during the following 12 months.
• If termination without “Cause” or for “Good Reason” occurs within three months prior to or 12 months after a change of control: lump sum equal to then-current annual base salary and target annual bonus, COBRA premium reimbursement for up to 12 months if timely elected, and accelerated vesting of outstanding equity awards.

Why it may matter Item 5.02 was reported; the item covers employment agreements and the related compensation and termination/change-of-control protections for two named executive officers. The filing does not show why the insider traded or why the company acted.